Funding for this research was provided by:
Text and Data Mining valid from 2020-01-30
Received: 19 November 2019
Accepted: 13 January 2020
First Online: 30 January 2020
Ethics approval and consent to participate
: A written informed consent was obtained from all patients prior to study participation.
: Not applicable.
: Arthur Fridman and Ansuman Bagchi are employees of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA and may own stock in the company. Luigi Aurisicchio and Gennaro Ciliberto were both employees of IRBM P. Angeletti, a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA at the time of the study (2006–2009) and may own stock in the company. They both contributed to the initial generation of the V934/V935 vaccine. Alberto Chiappori is on the speaker bureau of Genentech, Celgene, Takeda and Merck; is on the Ad Board of BMS, Astra Zeneca, Amgen, AbbVie and Pfizer; and has received research funding from BMS, Astra Zeneca and Novartis.